<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895102</url>
  </required_header>
  <id_info>
    <org_study_id>M11-032</org_study_id>
    <nct_id>NCT00895102</nct_id>
  </id_info>
  <brief_title>Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers</brief_title>
  <official_title>An Open-Label Randomized, Crossover Study to Evaluate the Bioavailability of ABT-333 Tablets Versus Capsules, and A Double-blind, Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending Doses of ABT-333 Tablets Versus Placebo in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the bioavailability, pharmacokinetic and safety
      profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine relative bioavailability of the ABT-333 tablet formulation compared to the FIH capsule formulation</measure>
    <time_frame>2 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate single dose safety and tolerability of a ABT-333 tablet formulation relative to placebo</measure>
    <time_frame>2 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate single dose pharmacokinetics of a ABT-333 tablet formulation</measure>
    <time_frame>2 days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>1. ABT-333 Capsule vs ABT-333 Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. ABT-333 Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, QD, single ascending doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333 Tablet</intervention_name>
    <description>See Arm Description for more information.</description>
    <arm_group_label>1. ABT-333 Capsule vs ABT-333 Tablet</arm_group_label>
    <arm_group_label>2. ABT-333 Tablet</arm_group_label>
    <arm_group_label>3. Placebo</arm_group_label>
    <other_name>ABT-333</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See Arm Description for more information.</description>
    <arm_group_label>2. ABT-333 Tablet</arm_group_label>
    <arm_group_label>3. Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333 Capsule</intervention_name>
    <description>See arm description for more information</description>
    <arm_group_label>1. ABT-333 Capsule vs ABT-333 Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  overall healthy subjects;

          -  non-childbearing potential females included

        Exclusion Criteria:

          -  history of significant sensitivity to any drug;

          -  positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab;

          -  history of gastrointestinal issues or procedures;

          -  history of seizures, diabetes or cancer (except basal cell carcinoma);

          -  clinically significant cardiovascular, respiratory (except mild asthma), renal,
             gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical
             illness or psychiatric disorder;

          -  use of tobacco or nicotine-containing products with the 6-month period prior to study
             drug administration;

          -  donation or loss of 550 mL or more blood volume or receipt of a transfusion of any
             blood product within 8 weeks prior to study drug administration;

          -  abnormal screening laboratory results that are considered clinically significant by
             the investigator;

          -  current enrollment in another clinical study;

          -  previous enrollment in this study;

          -  recent (6-month) history of drug/alcohol abuse that could preclude adherence to the
             protocol;

          -  pregnant or breastfeeding female;

          -  requirement for any OTC and/or prescription medication, vitamins and/or herbal
             supplements on a regular basis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 19441</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>October 12, 2010</last_update_submitted>
  <last_update_submitted_qc>October 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel Cohen, MD/Study Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Bioavailability (BA)</keyword>
  <keyword>Single Ascending Dose (SAD)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

